Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D
Immunodiagnosis and Immunotherapy Unit, S. Orsola-Malpighi Hospital, Bologna, Italy.
Biotherapy. 1996;9(1-3):123-32. doi: 10.1007/BF02628669.
As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.
由于传统治疗方法无效，D3期前列腺癌患者的生存率很低。报告表明存在针对前列腺癌肿瘤相关抗原（TAA）的体液免疫和细胞介导免疫（CMI）。这些观察结果促使我们用一种体外产生的转移因子（TF）治疗D3期前列腺癌患者，该转移因子能够在体外和体内转移针对膀胱和前列腺TAA的CMI。50名患者进入本研究，每月接受一次2 - 5单位特异性TF的肌肉注射。随访时间为1至9年，结果显示2例患者完全缓解，6例部分缓解，14例转移性疾病无进展。中位生存期为126周，高于文献报道的同阶段患者的生存率。
